Micro-costing analysis from Italian Guidelines for the management of sporadic primary hyperparathyroidism

Introduction: Primary hyperparathyroidism (PHPT) is a common endocrine disorder, primarily caused by single adenomas or multiglandular disease. This study evaluates the economic impact of different PHPT treatment approaches from both the Italian National Health Service and societal perspectives. Me...

Full description

Saved in:
Bibliographic Details
Main Authors: Ilaria Valentini, Michele Basile, Fabio Vescini, Giorgio Borretta, Iacopo Chiodini, Marco Boniardi, Marina Carotti, Elena Castellano, Cristiana Cipriani, Cristina Eller-Vainicher, Sandro Giannini, Maurizio Iacobone, Antonio Stefano Salcuni, Federica Saponaro, Stefano Spiezia, Annibale Versari, Guido Zavatta, Zuzana Mitrova, Rosella Saulle, Alexia Giovanazzi, Roberto Novizio, Agostino Paoletta, Enrico Papini, Agnese Persichetti, Irene Samperi, Alessandro Scoppola, Pietro Giorgio Calò, Filomena Cetani, Luisella Cianferotti, Sabrina Corbetta, Maria Luisa De Rimini, Alberto Falchetti, Stefano Laureti, Bruno Madeo, Claudio Marcocci, Sandro Mazzaferro, Vittorio Miele, Salvatore Minisola, Andrea Palermo, Jessica Pepe, Alfredo Scillitani, Franco Grimaldi, Renato Cozzi, Roberto Attanasio
Format: Article
Language:English
Published: AboutScience Srl 2025-07-01
Series:Global & Regional Health Technology Assessment
Subjects:
Online Access:https://journals.aboutscience.eu/index.php/grhta/article/view/3531
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849251909017272320
author Ilaria Valentini
Michele Basile
Fabio Vescini
Giorgio Borretta
Iacopo Chiodini
Marco Boniardi
Marina Carotti
Elena Castellano
Cristiana Cipriani
Cristina Eller-Vainicher
Sandro Giannini
Maurizio Iacobone
Antonio Stefano Salcuni
Federica Saponaro
Stefano Spiezia
Annibale Versari
Guido Zavatta
Zuzana Mitrova
Rosella Saulle
Alexia Giovanazzi
Roberto Novizio
Agostino Paoletta
Enrico Papini
Agnese Persichetti
Irene Samperi
Alessandro Scoppola
Pietro Giorgio Calò
Filomena Cetani
Luisella Cianferotti
Sabrina Corbetta
Maria Luisa De Rimini
Alberto Falchetti
Stefano Laureti
Bruno Madeo
Claudio Marcocci
Sandro Mazzaferro
Vittorio Miele
Salvatore Minisola
Andrea Palermo
Jessica Pepe
Alfredo Scillitani
Franco Grimaldi
Renato Cozzi
Roberto Attanasio
author_facet Ilaria Valentini
Michele Basile
Fabio Vescini
Giorgio Borretta
Iacopo Chiodini
Marco Boniardi
Marina Carotti
Elena Castellano
Cristiana Cipriani
Cristina Eller-Vainicher
Sandro Giannini
Maurizio Iacobone
Antonio Stefano Salcuni
Federica Saponaro
Stefano Spiezia
Annibale Versari
Guido Zavatta
Zuzana Mitrova
Rosella Saulle
Alexia Giovanazzi
Roberto Novizio
Agostino Paoletta
Enrico Papini
Agnese Persichetti
Irene Samperi
Alessandro Scoppola
Pietro Giorgio Calò
Filomena Cetani
Luisella Cianferotti
Sabrina Corbetta
Maria Luisa De Rimini
Alberto Falchetti
Stefano Laureti
Bruno Madeo
Claudio Marcocci
Sandro Mazzaferro
Vittorio Miele
Salvatore Minisola
Andrea Palermo
Jessica Pepe
Alfredo Scillitani
Franco Grimaldi
Renato Cozzi
Roberto Attanasio
author_sort Ilaria Valentini
collection DOAJ
description Introduction: Primary hyperparathyroidism (PHPT) is a common endocrine disorder, primarily caused by single adenomas or multiglandular disease. This study evaluates the economic impact of different PHPT treatment approaches from both the Italian National Health Service and societal perspectives. Methods: A micro-costing approach was used to estimate the costs of surgical and non-surgical treatments. Data were gathered through a survey among panel members responsible for the Italian PHPT treatment guidelines, ensuring alignment with national clinical practice. The survey examined various cost components, including diagnostic tests, pre-hospitalization assessments, surgery duration, drug use, healthcare professionals involved, disposable materials, and follow-up care requirements. Results: The total cost for PHPT diagnosis and comorbidity assessment is € 887.96. Parathyroidectomy (PTX) costs € 4,588.00. Non-surgical alternatives, including pharmacological treatment (€ 953.34 annually) and active surveillance (€ 197.42 annually), result in cumulative 30-year costs of € 28,590 and € 5,910, respectively. Since PTX is typically performed at age 55, pharmacological treatment over 30 years incurs an additional € 22,876 per patient compared to surgery. Conclusions: Despite its higher upfront cost, PTX demonstrated long-term cost efficiency due to the relatively low rates of follow-up complications and the absence of recurring annual costs associated with conservative strategies.
format Article
id doaj-art-6a7b487a268b4d748e4e9568519729b0
institution Kabale University
issn 2284-2403
2283-5733
language English
publishDate 2025-07-01
publisher AboutScience Srl
record_format Article
series Global & Regional Health Technology Assessment
spelling doaj-art-6a7b487a268b4d748e4e9568519729b02025-08-20T03:56:46ZengAboutScience SrlGlobal & Regional Health Technology Assessment2284-24032283-57332025-07-0112110.33393/grhta.2025.3531Micro-costing analysis from Italian Guidelines for the management of sporadic primary hyperparathyroidismIlaria Valentini0Michele Basile1Fabio Vescini2Giorgio Borretta3Iacopo Chiodini4Marco Boniardi5Marina Carotti6Elena Castellano7Cristiana Cipriani8Cristina Eller-Vainicher9Sandro Giannini10Maurizio Iacobone11Antonio Stefano Salcuni12Federica Saponaro13Stefano Spiezia14Annibale Versari15Guido Zavatta16Zuzana Mitrova17Rosella Saulle18Alexia Giovanazzi19Roberto Novizio20Agostino Paoletta21Enrico Papini22Agnese Persichetti23Irene Samperi24Alessandro Scoppola25Pietro Giorgio Calò26Filomena Cetani27Luisella Cianferotti28Sabrina Corbetta29Maria Luisa De Rimini30Alberto Falchetti31Stefano Laureti32Bruno Madeo33Claudio Marcocci34Sandro Mazzaferro35Vittorio Miele36Salvatore Minisola37Andrea Palermo38Jessica Pepe39Alfredo Scillitani40Franco Grimaldi41Renato Cozzi42Roberto Attanasio43High School of Economy and Management of Health Systems, Catholic University of Sacred Heart, Rome - Italy and Department of Medicine and Surgery, University of Perugia, Perugia - ItalyHigh School of Economy and Management of Health Systems, Catholic University of Sacred Heart, Rome - ItalyEndocrinology Unit, Azienda Sanitaria-Universitaria Friuli Centrale, P.O. Santa Maria della Misericordia, Udine - ItalyDepartment of Endocrinology, Diabetes and Metabolism, Ospedale Santa Croce and Carle Hospital, Cuneo - ItalyEndocrinology Department, ASST Grande Ospedale Metropolitano di Niguarda, Milan - Italy and Department of Biotechnology and Translational Medicine, University of Milan, Milan - ItalyEndocrine Surgery Unit, General Oncologic and Mini-invasive Surgery Department, ASST Grande Ospedale Metropolitano di Niguarda, Milan - ItalyDepartment of Radiology, AOU delle Marche, Ancona, - ItalyDepartment of Endocrinology, Diabetes and Metabolism, Ospedale Santa Croce and Carle Hospital, Cuneo - ItalyDepartment of Clinical, Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome - ItalyEndocrinology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan - ItalyClinica Medica 1, Department of Medicine, University of Padova, Padova - ItalyEndocrine Surgery Unit, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova - ItalyEndocrinology Unit, Azienda Sanitaria-Universitaria Friuli Centrale, P.O. Santa Maria della Misericordia, Udine - ItalyDepartment of Surgical, Medical, and Molecular Pathology and Critical Care Medicine, University Pisa, Pisa - ItalyDepartment of Endocrine and Ultrasound- Guided Surgery, Ospedale del Mare, Naples - ItalyNuclear Medicine, Azienda Unità Sanitaria Locale–IRCCS di Reggio Emilia, Reggio Emilia - ItalyDivision of Endocrinology and Diabetes Prevention and Care, IRCCS AOU di Bologna, Bologna - Italy and Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum University of Bologna, Bologna - ItalyDepartment of Epidemiology, Lazio Region Health Service, ASL Roma 1, Rome - ItalyDepartment of Epidemiology, Lazio Region Health Service, ASL Roma 1, Rome - ItalyAzienda Provinciale per i Servizi Sanitari della Provincia Autonoma di Trento, Trento - ItalyEndocrinology Unit, Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome - ItalyEndocrinology,, ULSS6 Euganea, Padova - ItalyEndocrinology, Ospedale Regina Apostolorum, Lifenet Health Group, Albano Laziale (RM) - ItalyMinistry of Interior - Department of Firefighters, Public Rescue and Civil Defense, Rome and Department of Human Sciences and Promotion of the Quality of Life, San Raffaele Roma Open University, Rome - ItalyEndocrinology, ASL Novara, Novara - ItalyUOSD Endocrinology, ASL Roma 1, Rome - ItalySIUEC Past President, Department of Surgical Sciences, University of Cagliari, Cagliari - ItalyEndocrine Unit 2, Department of Clinical and Experimental Medicine, University of Pisa, Pisa - ItalyDepartment of Experimental, Clinical and Biomedical Sciences, University of Florence; Bone Metabolic Diseases Unit, AOU Careggi, Florence - ItalyBone Metabolism and Diabetes, IRCCS Istituto Auxologico Italiano, Milan - Italy and Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan - ItalyAIMN President, Nuclear Medicine Unit, AORN Ospedali dei Colli, Naples - ItalyEndocrinology Department, ASST Grande Ospedale Metropolitano di Niguarda, Milan - ItalyGeneral Practitioner, USL Umbria 1, Magione (Perugia) - ItalyUnit of Endocrinology, Department of Medical Specialties, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria di Modena, Modena - ItalyDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa - ItalyNephrology Unit at Policlinico Umberto I Hospital and Department of Translation and Precision Medicine, Sapienza University of Rome - ItalyDepartment of Emergency Radiology, Careggi University Hospital, Florence - ItalyDepartment of Clinical, Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Rome - ItalyUnit of Endocrinology and Diabetes, Campus Bio-Medico University, Rome - Italy and Unit of Metabolic Bone and Thyroid Disorders, Fondazione Policlinico Universitario Campus Bio-Medico, Rome - ItalyDepartment of Clinical, Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome - ItalyUnit of Endocrinology, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo (FG) - ItalyItalian Association of Clinical Endocrinologists past President, Udine - ItalyEndocrinology Department, ASST Grande Ospedale Metropolitano di Niguarda, Milan - Italy and Italian Association of Clinical Endocrinologists past President, Milan - ItalyItalian Association of Clinical Endocrinologists Scientific Committee, Milan - Italy Introduction: Primary hyperparathyroidism (PHPT) is a common endocrine disorder, primarily caused by single adenomas or multiglandular disease. This study evaluates the economic impact of different PHPT treatment approaches from both the Italian National Health Service and societal perspectives. Methods: A micro-costing approach was used to estimate the costs of surgical and non-surgical treatments. Data were gathered through a survey among panel members responsible for the Italian PHPT treatment guidelines, ensuring alignment with national clinical practice. The survey examined various cost components, including diagnostic tests, pre-hospitalization assessments, surgery duration, drug use, healthcare professionals involved, disposable materials, and follow-up care requirements. Results: The total cost for PHPT diagnosis and comorbidity assessment is € 887.96. Parathyroidectomy (PTX) costs € 4,588.00. Non-surgical alternatives, including pharmacological treatment (€ 953.34 annually) and active surveillance (€ 197.42 annually), result in cumulative 30-year costs of € 28,590 and € 5,910, respectively. Since PTX is typically performed at age 55, pharmacological treatment over 30 years incurs an additional € 22,876 per patient compared to surgery. Conclusions: Despite its higher upfront cost, PTX demonstrated long-term cost efficiency due to the relatively low rates of follow-up complications and the absence of recurring annual costs associated with conservative strategies. https://journals.aboutscience.eu/index.php/grhta/article/view/3531GuidelinesMicro-Costing AnalysisParathyroidectomyPrimary hyperparathyroidism
spellingShingle Ilaria Valentini
Michele Basile
Fabio Vescini
Giorgio Borretta
Iacopo Chiodini
Marco Boniardi
Marina Carotti
Elena Castellano
Cristiana Cipriani
Cristina Eller-Vainicher
Sandro Giannini
Maurizio Iacobone
Antonio Stefano Salcuni
Federica Saponaro
Stefano Spiezia
Annibale Versari
Guido Zavatta
Zuzana Mitrova
Rosella Saulle
Alexia Giovanazzi
Roberto Novizio
Agostino Paoletta
Enrico Papini
Agnese Persichetti
Irene Samperi
Alessandro Scoppola
Pietro Giorgio Calò
Filomena Cetani
Luisella Cianferotti
Sabrina Corbetta
Maria Luisa De Rimini
Alberto Falchetti
Stefano Laureti
Bruno Madeo
Claudio Marcocci
Sandro Mazzaferro
Vittorio Miele
Salvatore Minisola
Andrea Palermo
Jessica Pepe
Alfredo Scillitani
Franco Grimaldi
Renato Cozzi
Roberto Attanasio
Micro-costing analysis from Italian Guidelines for the management of sporadic primary hyperparathyroidism
Global & Regional Health Technology Assessment
Guidelines
Micro-Costing Analysis
Parathyroidectomy
Primary hyperparathyroidism
title Micro-costing analysis from Italian Guidelines for the management of sporadic primary hyperparathyroidism
title_full Micro-costing analysis from Italian Guidelines for the management of sporadic primary hyperparathyroidism
title_fullStr Micro-costing analysis from Italian Guidelines for the management of sporadic primary hyperparathyroidism
title_full_unstemmed Micro-costing analysis from Italian Guidelines for the management of sporadic primary hyperparathyroidism
title_short Micro-costing analysis from Italian Guidelines for the management of sporadic primary hyperparathyroidism
title_sort micro costing analysis from italian guidelines for the management of sporadic primary hyperparathyroidism
topic Guidelines
Micro-Costing Analysis
Parathyroidectomy
Primary hyperparathyroidism
url https://journals.aboutscience.eu/index.php/grhta/article/view/3531
work_keys_str_mv AT ilariavalentini microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism
AT michelebasile microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism
AT fabiovescini microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism
AT giorgioborretta microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism
AT iacopochiodini microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism
AT marcoboniardi microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism
AT marinacarotti microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism
AT elenacastellano microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism
AT cristianacipriani microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism
AT cristinaellervainicher microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism
AT sandrogiannini microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism
AT maurizioiacobone microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism
AT antoniostefanosalcuni microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism
AT federicasaponaro microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism
AT stefanospiezia microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism
AT annibaleversari microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism
AT guidozavatta microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism
AT zuzanamitrova microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism
AT rosellasaulle microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism
AT alexiagiovanazzi microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism
AT robertonovizio microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism
AT agostinopaoletta microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism
AT enricopapini microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism
AT agnesepersichetti microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism
AT irenesamperi microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism
AT alessandroscoppola microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism
AT pietrogiorgiocalo microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism
AT filomenacetani microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism
AT luisellacianferotti microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism
AT sabrinacorbetta microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism
AT marialuisaderimini microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism
AT albertofalchetti microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism
AT stefanolaureti microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism
AT brunomadeo microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism
AT claudiomarcocci microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism
AT sandromazzaferro microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism
AT vittoriomiele microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism
AT salvatoreminisola microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism
AT andreapalermo microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism
AT jessicapepe microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism
AT alfredoscillitani microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism
AT francogrimaldi microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism
AT renatocozzi microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism
AT robertoattanasio microcostinganalysisfromitalianguidelinesforthemanagementofsporadicprimaryhyperparathyroidism